# ðŸ“± Ù…Ø¹Ø§ÙŠÙ†Ø© Ø§Ù„Ù…ÙˆØ¨Ø§ÙŠÙ„: Dormicum (Adaptive UI)

Ø¥Ø¬Ø§Ø¨Ø© Ø¹Ù„Ù‰ Ø³Ø¤Ø§Ù„Ùƒ: **Ù†Ø¹Ù…ØŒ Ù†Ù…Ù„Ùƒ Ø§Ù„ØªØ­ÙƒÙ… Ø§Ù„ÙƒØ§Ù…Ù„.**
Ø¨Ù…Ø§ Ø£Ù† Ø§Ù„Ø¨ÙŠØ§Ù†Ø§Øª ØªØ£ØªÙŠ ÙƒÙ€ HTML Ù…Ù‡ÙŠÙƒÙ„ØŒ ÙŠÙ…ÙƒÙ†Ù†Ø§ ÙƒØ³Ø± "Ù‚Ø§Ù„Ø¨ Ø§Ù„Ø¬Ø¯ÙˆÙ„" ÙˆØªØ­ÙˆÙŠÙ„Ù‡ Ø¥Ù„Ù‰ **Ø¨Ø·Ø§Ù‚Ø§Øª (Cards)** Ø£Ùˆ **Ù‚ÙˆØ§Ø¦Ù… (Lists)** ØªÙ†Ø§Ø³Ø¨ Ø´Ø§Ø´Ø© Ø§Ù„Ù…ÙˆØ¨Ø§ÙŠÙ„ Ø§Ù„Ø·ÙˆÙ„ÙŠØ©.

## Ù…Ù‚Ø§Ø±Ù†Ø© Ø§Ù„ØªØ¬Ø±Ø¨Ø© (User Experience)
Ø¨Ø¯Ù„Ø§Ù‹ Ù…Ù† Ø¥Ø¬Ø¨Ø§Ø± Ø§Ù„Ø·Ø¨ÙŠØ¨ Ø¹Ù„Ù‰ Ø§Ù„ØªÙ…Ø±ÙŠØ± ÙŠÙ…ÙŠÙ†Ø§Ù‹ ÙˆÙŠØ³Ø§Ø±Ø§Ù‹ (Scroll Horizontal) ÙÙŠ Ø¬Ø¯ÙˆÙ„ØŒ Ø³Ù†Ø¹Ø±Ø¶ Ù„Ù‡ Ø§Ù„Ø¨ÙŠØ§Ù†Ø§Øª Ù‡ÙƒØ°Ø§:

### ðŸ”½ Ù‚Ø³Ù… Ø§Ù„Ø¬Ø±Ø¹Ø§Øª Ø±Ù‚Ù… 1 (Card View)
> ðŸ“± **Mobile Card**
> ### INTRAVENOUSLY Sedation/anxiolysis/amnesia for procedures (See INDICATIONS AND USAGE): Narcotic premedication results in less variability in patient response and a reduction in dosage of midazolam. For peroral procedures, the use of an appropriate topical anesthetic is recommended. For bronchoscopic procedures, the use of narcotic premedication is recommended. Midazolam hydrochloride 1 mg/mL formulation is recommended for sedation/anxiolysis/amnesia for procedures to facilitate slower injection. Both the 1 mg/mL and the 5 mg/mL formulations may be diluted with 0.9% sodium chloride or 5% dextrose in water.
> * **The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0.08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The dose must be individualized and reduced when IM midazolam is administered to patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60 or more years of age, and patients who have received concomitant narcotics or other CNS depressants (see ADVERSE REACTIONS). In a study of patients 60 years or older, who did not receive concomitant administration of narcotics, 2 to 3 mg (0.02 to 0.05 mg/kg) of midazolam produced adequate sedation during the preoperative period. The dose of 1 mg IM midazolam hydrochloride may suffice for some older patients if the anticipated intensity and duration of sedation is less critical. As with any potential respiratory depressant, these patients require observation for signs of cardiorespiratory depression after receiving IM midazolam. Onset is within 15 minutes, peaking at 30 to 60 minutes. It can be administered concomitantly with atropine sulfate or scopolamine hydrochloride and reduced doses of narcotics.:** When used for sedation/anxiolysis/amnesia for a procedure, dosage must be individualized and titrated. Midazolam hydrochloride should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. Individual response will vary with age, physical status and concomitant medications, but may also vary independent of these factors. (See WARNINGSconcerning cardiac/respiratory arrest/airway obstruction/ hypoventilation.) Healthy Adults Below the Age of 60:Titrate slowly to the desired effect, (e.g., the initiation of slurred speech). Some patients may respond to as little as 1 mg. No more than 2.5 mg should be given over a period of at least 2 minutes. Wait an additional 2 or more minutes to fully evaluate the sedative effect. If further titration is necessary, continue to titrate, using small increments, to the appropriate level of sedation. Wait an additional 2 or more minutes after each increment to fully evaluate the sedative effect. A total dose greater than 5 mg is not usually necessary to reach the desired endpoint. If narcotic premedication or other CNS depressants are used, patients will require approximately 30% less midazolam than unpremedicated patients. Patients Age 60 or Older, and Debilitated or Chronically Ill Patients:Because the danger of hypoventilation, airway obstruction, or apnea is greater in elderly patients and those with chronic disease states or decreased pulmonary reserve, and because the peak effect may take longer in these patients, increments should be smaller and the rate of injection slower. Titrate slowly to the desired effect, (e.g., the initiation of slurred speech). Some patients may respond to as little as 1 mg. No more than 1.5 mg should be given over a period of no less than 2 minutes. Wait an additional 2 or more minutes to fully evaluate the sedative effect. If additional titration is necessary, it should be given at a rate of no more than 1 mg over a period of 2 minutes, waiting an additional 2 or more minutes each time to fully evaluate the sedative effect. Total doses greater than 3.5 mg are not usually necessary. If concomitant CNS depressant premedications are used in these patients, they will require at least 50% less midazolam than healthy young unpremedicated patients. Maintenance Dose:Additional doses to maintain the desired level of sedation may be given in increments of 25% of the dose used to first reach the sedative endpoint, but again only by slow titration, especially in the elderly and chronically ill or debilitated patient. These additional doses should be given only after a thorough clinical evaluation clearly indicates the need for additional sedation.


> ðŸ“± **Mobile Card**
> ### Induction of Anesthesia: For induction of general anesthesia, before administration of other anesthetic agents.
> * **The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0.08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The dose must be individualized and reduced when IM midazolam is administered to patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60 or more years of age, and patients who have received concomitant narcotics or other CNS depressants (see ADVERSE REACTIONS). In a study of patients 60 years or older, who did not receive concomitant administration of narcotics, 2 to 3 mg (0.02 to 0.05 mg/kg) of midazolam produced adequate sedation during the preoperative period. The dose of 1 mg IM midazolam hydrochloride may suffice for some older patients if the anticipated intensity and duration of sedation is less critical. As with any potential respiratory depressant, these patients require observation for signs of cardiorespiratory depression after receiving IM midazolam. Onset is within 15 minutes, peaking at 30 to 60 minutes. It can be administered concomitantly with atropine sulfate or scopolamine hydrochloride and reduced doses of narcotics.:** Individual response to the drug is variable, particularly when a narcotic premedication is not used. The dosage should be titrated to the desired effect according to the patient's age and clinical status. When midazolam is used before other intravenous agents for induction of anesthesia, the initial dose of each agent may be significantly reduced, at times to as low as 25% of the usual initial dose of the individual agents. Unpremedicated Patients:In the absence of premedication, an average adult under the age of 55 years will usually require an initial dose of 0.3 to 0.35 mg/kg for induction, administered over 20 to 30 seconds and allowing 2 minutes for effect. If needed to complete induction, increments of approximately 25% of the patient's initial dose may be used; induction may instead be completed with inhalational anesthetics. In resistant cases, up to 0.6 mg/kg total dose may be used for induction, but such larger doses may prolong recovery. Unpremedicated patients over the age of 55 years usually require less midazolam for induction; an initial dose of 0.3 mg/kg is recommended. Unpremedicated patients with severe systemic disease or other debilitation usually require less midazolam for induction. An initial dose of 0.2 to 0.25 mg/kg will usually suffice; in some cases, as little as 0.15 mg/kg may suffice. Premedicated Patients:When the patient has received sedative or narcotic premedication, particularly narcotic premedication, the range of recommended doses is 0.15 to 0.35 mg/kg. In average adults below the age of 55 years, a dose of 0.25 mg/kg, administered over 20 to 30 seconds and allowing 2 minutes for effect, will usually suffice. The initial dose of 0.2 mg/kg is recommended for good risk (ASA I & II) surgical patients over the age of 55 years. In some patients with severe systemic disease or debilitation, as little as 0.15 mg/kg may suffice. Narcotic premedication frequently used during clinical trials included fentanyl (1.5 to 2 mcg/kg IV, administered 5 minutes before induction), morphine (dosage individualized, up to 0.15 mg/kg IM), and meperidine (dosage individualized, up to 1 mg/kg IM). Sedative premedications were hydroxyzine pamoate (100 mg orally) and sodium secobarbital (200 mg orally). Except for intravenous fentanyl, administered 5 minutes before induction, all other premedications should be administered approximately 1 hour prior to the time anticipated for midazolam induction.


> ðŸ“± **Mobile Card**
> ### Injectable midazolam hydrochloride can also be used during maintenance of anesthesia, for surgical procedures, as a component of balanced anesthesia. Effective narcotic premedication is especially recommended in such cases.
> * **The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0.08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The dose must be individualized and reduced when IM midazolam is administered to patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60 or more years of age, and patients who have received concomitant narcotics or other CNS depressants (see ADVERSE REACTIONS). In a study of patients 60 years or older, who did not receive concomitant administration of narcotics, 2 to 3 mg (0.02 to 0.05 mg/kg) of midazolam produced adequate sedation during the preoperative period. The dose of 1 mg IM midazolam hydrochloride may suffice for some older patients if the anticipated intensity and duration of sedation is less critical. As with any potential respiratory depressant, these patients require observation for signs of cardiorespiratory depression after receiving IM midazolam. Onset is within 15 minutes, peaking at 30 to 60 minutes. It can be administered concomitantly with atropine sulfate or scopolamine hydrochloride and reduced doses of narcotics.:** Incremental injections of approximately 25% of the induction dose should be given in response to signs of lightening of anesthesia and repeated as necessary.


> ðŸ“± **Mobile Card**
> ### CONTINUOUS INFUSION For continuous infusion, midazolam hydrochloride 5 mg/mL formulation is recommended diluted to a concentration of 0.5 mg/mL with 0.9% sodium chloride or 5% dextrose in water.
> * **The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0.08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The dose must be individualized and reduced when IM midazolam is administered to patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60 or more years of age, and patients who have received concomitant narcotics or other CNS depressants (see ADVERSE REACTIONS). In a study of patients 60 years or older, who did not receive concomitant administration of narcotics, 2 to 3 mg (0.02 to 0.05 mg/kg) of midazolam produced adequate sedation during the preoperative period. The dose of 1 mg IM midazolam hydrochloride may suffice for some older patients if the anticipated intensity and duration of sedation is less critical. As with any potential respiratory depressant, these patients require observation for signs of cardiorespiratory depression after receiving IM midazolam. Onset is within 15 minutes, peaking at 30 to 60 minutes. It can be administered concomitantly with atropine sulfate or scopolamine hydrochloride and reduced doses of narcotics.:** Usual Adult Dose:If a loading dose is necessary to rapidly initiate sedation, 0.01 to 0.05 mg/kg (approximately 0.5 to 4 mg for a typical adult) may be given slowly or infused over several minutes. This dose may be repeated at 10 to 15 minute intervals until adequate sedation is achieved. For maintenance of sedation, the usual initial infusion rate is 0.02 to 0.1 mg/kg/hr (1 to 7 mg/hr). Higher loading or maintenance infusion rates may occasionally be required in some patients. The lowest recommended doses should be used in patients with residual effects from anesthetic drugs, or in those concurrently receiving other sedatives or opioids. Individual response to midazolam is variable. The infusion rate should be titrated to the desired level of sedation, taking into account the patient's age, clinical status and current medications. In general, midazolam should be infused at the lowest rate that produces the desired level of sedation. Assessment of sedation should be performed at regular intervals and the midazolam infusion rate adjusted up or down by 25% to 50% of the initial infusion rate so as to assure adequate titration of sedation level. Larger adjustments or even a small incremental dose may be necessary if rapid changes in the level of sedation are indicated. In addition, the infusion rate should be decreased by 10% to 25% every few hours to find the minimum effective infusion rate. Finding the minimum effective infusion rate decreases the potential accumulation of midazolam and provides for the most rapid recovery once the infusion is terminated. Patients who exhibit agitation, hypertension, or tachycardia in response to noxious stimulation, but who are otherwise adequately sedated, may benefit from concurrent administration of an opioid analgesic. Addition of an opioid will generally reduce the minimum effective midazolam hydrochloride infusion rate.


> ðŸ“± **Mobile Card**
> ### PEDIATRIC PATIENTS
> * **The recommended premedication dose of midazolam for good risk (ASA Physical Status I & II) adult patients below the age of 60 years is 0.07 to 0.08 mg/kg IM (approximately 5 mg IM) administered up to 1 hour before surgery. The dose must be individualized and reduced when IM midazolam is administered to patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60 or more years of age, and patients who have received concomitant narcotics or other CNS depressants (see ADVERSE REACTIONS). In a study of patients 60 years or older, who did not receive concomitant administration of narcotics, 2 to 3 mg (0.02 to 0.05 mg/kg) of midazolam produced adequate sedation during the preoperative period. The dose of 1 mg IM midazolam hydrochloride may suffice for some older patients if the anticipated intensity and duration of sedation is less critical. As with any potential respiratory depressant, these patients require observation for signs of cardiorespiratory depression after receiving IM midazolam. Onset is within 15 minutes, peaking at 30 to 60 minutes. It can be administered concomitantly with atropine sulfate or scopolamine hydrochloride and reduced doses of narcotics.:** UNLIKE ADULT PATIENTS, PEDIATRIC PATIENTS GENERALLY RECEIVE INCREMENTS OF MIDAZOLAM HYDROCHLORIDE ON A MG/KG BASIS. As a group, pediatric patients generally require higher dosages of midazolam hydrochloride (mg/kg) than do adults. Younger (less than six years) pediatric patients may require higher dosages (mg/kg) than older pediatric patients, and may require close monitoring (see tables below). In obese PEDIATRIC PATIENTS, the dose should be calculated based on ideal body weight. When midazolam is given in conjunction with opioids or other sedatives, the potential for respiratory depression, airway obstruction, or hypoventilation is increased. For appropriate patient monitoring, see Boxed WARNING, WARNINGS, and DOSAGE AND ADMINISTRATION, Monitoring. The health care practitioner who uses this medication in pediatric patients should be aware of and follow accepted professional guidelines for pediatric sedation appropriate to their situation.


---

### ðŸ”½ Ù‚Ø³Ù… Ø§Ù„Ø¬Ø±Ø¹Ø§Øª Ø±Ù‚Ù… 2 (Card View)
> ðŸ“± **Mobile Card**
> ### Responds readily to name spoken in normal tone
> * **Speech:** normal
> * **Facial Expression:** normal
> * **Eyes:** clear, no ptosis
> * **Composite Score:** 5 (alert)


> ðŸ“± **Mobile Card**
> ### Lethargic response to name spoken in normal tone
> * **Speech:** mild slowing or thickening
> * **Facial Expression:** mild relaxation
> * **Eyes:** glazed or mild ptosis (less than half the eye)
> * **Composite Score:** 4


> ðŸ“± **Mobile Card**
> ### Responds only after name is called loudly and/or repeatedly
> * **Speech:** slurring or prominent slowing
> * **Facial Expression:** marked relaxation (slack jaw)
> * **Eyes:** glazed and marked ptosis (half the eye or more)
> * **Composite Score:** 3


> ðŸ“± **Mobile Card**
> ### Responds only after mild prodding or shaking
> * **Speech:** Few recognizable words
> * **Facial Expression:** âˆ’
> * **Eyes:** âˆ’
> * **Composite Score:** 2


> ðŸ“± **Mobile Card**
> ### Does not respond to mild prodding or shaking
> * **Speech:** âˆ’
> * **Facial Expression:** âˆ’
> * **Eyes:** âˆ’
> * **Composite Score:** 1 (deep sleep)


---

### ðŸ”½ Ù‚Ø³Ù… Ø§Ù„Ø¬Ø±Ø¹Ø§Øª Ø±Ù‚Ù… 3 (Card View)
> ðŸ“± **Mobile Card**
> ### 1 to 2
> * **:** 16
> * **1 (deep sleep):** 6 (38%)
> * **2:** 4 (25%)
> * **3:** 3 (19%)
> * **4:** 3 (19%)
> * **5 (alert):** 0


> ðŸ“± **Mobile Card**
> ### >2 to 5
> * **:** 22
> * **1 (deep sleep):** 9 (41%)
> * **2:** 5(23%)
> * **3:** 8 (36%)
> * **4:** 0
> * **5 (alert):** 0


> ðŸ“± **Mobile Card**
> ### >5 to 12
> * **:** 34
> * **1 (deep sleep):** 1 (3%)
> * **2:** 6 (18%)
> * **3:** 22 (65%)
> * **4:** 5 (15%)
> * **5 (alert):** 0


> ðŸ“± **Mobile Card**
> ### >12 to 17
> * **:** 18
> * **1 (deep sleep):** 0
> * **2:** 4 (22%)
> * **3:** 14 (78%)
> * **4:** 0
> * **5 (alert):** 0


> ðŸ“± **Mobile Card**
> ### Total (1 to 17)
> * **:** 90
> * **1 (deep sleep):** 16 (18%)
> * **2:** 19 (21%)
> * **3:** 47 (52%)
> * **4:** 8 (9%)
> * **5 (alert):** 0


---

### ðŸ”½ Ù‚Ø³Ù… Ø§Ù„Ø¬Ø±Ø¹Ø§Øª Ø±Ù‚Ù… 4 (Card View)
> ðŸ“± **Mobile Card**
> ### INTRAVENOUSLY BY INTERMITTENT INJECTION For sedation/anxiolysis/amnesia prior to and during procedures or prior to anesthesia.
> * **Dosage Instruction:** USUAL PEDIATRIC DOSE (NON-NEONATAL) It should be recognized that the depth of sedation/anxiolysis needed for pediatric patients depends on the type of procedure to be performed. For example, simple light sedation/anxiolysis in the preoperative period is quite different from the deep sedation and analgesia required for an endoscopic procedure in a child. For this reason, there is a broad range of dosage. For all pediatric patients, regardless of the indications for sedation/anxiolysis, it is vital to titrate midazolam hydrochloride and other concomitant medications slowly to the desired clinical effect. The initial dose of midazolam should be administered over 2 to 3 minutes. Since midazolam hydrochloride is water soluble, it takes approximately three times longer than diazepam to achieve peak EEG effects, therefore one must wait an additional 2 to 3 minutes to fully evaluate the sedative effect before initiating a procedure or repeating a dose. If further sedation is necessary, continue to titrate with small increments until the appropriate level of sedation is achieved. If other medications capable of depressing the CNS are coadministered, the peak effect of those concomitant medications must be considered and the dose of midazolam adjusted. The importance of drug titration to effect is vital to the safe sedation/anxiolysis of the pediatric patient. The total dose of midazolam will depend on patient response, the type and duration of the procedure, as well as the type and dose of concomitant medications. Pediatric patients less than 6 months of age:Limited information is available in non-intubated pediatric patients less than 6 months of age. It is uncertain when the patient transfers from neonatal physiology to pediatric physiology, therefore the dosing recommendations are unclear. Pediatric patients less than 6 months of age are particularly vulnerable to airway obstruction and hypoventilation, therefore titration with small increments to clinical effect and careful monitoring are essential. Pediatric patients 6 months to 5 years of age:Initial dose 0.05 to 0.1 mg/kg. A total dose up to 0.6 mg/kg may be necessary to reach the desired endpoint but usually does not exceed 6 mg. Prolonged sedation and risk of hypoventilation may be associated with the higher doses. Pediatric patients 6 to 12 years of age:Initial dose 0.025 to 0.05 mg/kg; total dose up to 0.4 mg/kg may be needed to reach the desired endpoint but usually does not exceed 10 mg. Prolonged sedation and risk of hypoventilation may be associated with the higher doses. Pediatric patients 12 to 16 years of age:Should be dosed as adults. Prolonged sedation may be associated with higher doses; some patients in this age range will require higher than recommended adult doses but the total dose usually does not exceed 10 mg. The dose of midazolam hydrochloride must be reduced in patients premedicated with opioid or other sedative agents including midazolam. Higher risk or debilitated patients may require lower dosages whether or not concomitant sedating medications have been administered (see WARNINGS).


> ðŸ“± **Mobile Card**
> ### CONTINUOUS INTRAVENOUS INFUSION For sedation/anxiolysis/amnesia in critical care settings.
> * **Dosage Instruction:** USUAL PEDIATRIC DOSE (NON-NEONATAL) To initiate sedation, an intravenous loading dose of 0.05 to 0.2 mg/kg administered over at least 2 to 3 minutes can be used to establish the desired clinical effect IN PATIENTS WHOSE TRACHEA IS INTUBATED. (Midazolam should not be administered as a rapid intravenous dose.) This loading dose may be followed by a continuous intravenous infusion to maintain the effect. An infusion of midazolam hydrochloride injection has been used in patients whose trachea was intubated but who were allowed to breathe spontaneously. Assisted ventilation is recommended for pediatric patients who are receiving other central nervous system depressant medications such as opioids. Based on pharmacokinetic parameters and reported clinical experience, continuous intravenous infusions of midazolam should be initiated at a rate of 0.06 to 0.12 mg/kg/hr (1 to 2 mcg/kg/min). The rate of infusion can be increased or decreased (generally by 25% of the initial or subsequent infusion rate) as required, or supplemental intravenous doses of midazolam hydrochloride can be administered to increase or maintain the desired effect. Frequent assessment at regular intervals using standard pain/sedation scales is recommended. Drug elimination may be delayed in patients receiving erythromycin and/or other P450-3A4 enzyme inhibitors (see PRECAUTIONS, Drug Interactions section) and in patients with liver dysfunction, low cardiac output (especially those requiring inotropic support), and in neonates. Hypotension may be observed in patients who are critically ill, particularly those receiving opioids and/or when midazolam is rapidly administered. When initiating an infusion with midazolam in hemodynamically compromised patients, the usual loading dose of midazolam hydrochloride should be titrated in small increments and the patient monitored for hemodynamic instability, e.g., hypotension. These patients are also vulnerable to the respiratory depressant effects of midazolam and require careful monitoring of respiratory rate and oxygen saturation.


> ðŸ“± **Mobile Card**
> ### CONTINUOUS INTRAVENOUS INFUSION For sedation in critical care settings.
> * **Dosage Instruction:** USUAL NEONATAL DOSE Based on pharmacokinetic parameters and reported clinical experience in preterm and term neonates WHOSE TRACHEA WAS INTUBATED, continuous intravenous infusions of midazolam hydrochloride injection should be initiated at a rate of 0.03 mg/kg/hr (0.5 mcg/kg/min) in neonates <32 weeks and 0.06 mg/kg/hr (1 mcg/kg/min) in neonates >32 weeks. Intravenous loading doses should not be used in neonates, rather the infusion may be run more rapidly for the first several hours to establish therapeutic plasma levels. The rate of infusion should be carefully and frequently reassessed, particularly after the first 24 hours so as to administer the lowest possible effective dose and reduce the potential for drug accumulation. This is particularly important because of the potential adverse effects related to metabolism of the benzyl alcohol (see WARNINGS, Usage In Preterm Infants And Neonates). Hypotension may be observed in patients who are critically ill and in preterm and term infants, particularly those receiving fentanyl and/or when midazolam is administered rapidly. Due to an increased risk of apnea, extreme caution is advised when sedating preterm and former preterm patients whose trachea is not intubated.


---
